Sanofi Signs Benitec's closest competitor Voyager for $845M, page-5

I don't know. We keep blaming it on being in Australia but maybe something behind the curtains is behind all this. I just don't understand how these companies valuation can be so high and we are so low. Does big pharma see something in our science that makes it a very big risk? Bigger than voyager and and so forth. We keep saying wait for efficacy and then they will come but what about all these other companies that have not even a hint of efficacy that are getting billion dollar valuations? Something just isn't right. Maybe big pharma completely discounts TT-034 as commercially viable and is waiting for Tribetarna.